BridgeBio Pharma presented positive data from its Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM at the European Society of Cardiology (ESC) 2024, showcasing a significant increase in serum TTR levels in patients who switched to acoramidis. The FDA has accepted the company’s marketing application with a PDUFA date of November 29th, and BridgeBio has secured exclusive commercial rights for Europe with Bayer AG.